Recon: Novartis set to purchase Mariana for $1B; FDA requests more data on Dupixent for COPD

• Pasteurization inactivates H5N1 bird flu in milk, new FDA and academic studies confirm (STAT)
• FDA asks for more data on Dupixent in COPD in move that could delay a decision (Endpoints)
• Cigna lifts annual profit forecast (Reuters)
• CVS cuts annual profit forecast and flags challenges in 2025, shares fall 18% (Reuters)
• Pfizer lifts profit view on cost cuts, demand for COVID products (Reuters)
• US judge blocks some North Carolina restrictions on abortion pill (Reuters)
• J&J advances $6.48 billion settlement of talc cancer lawsuits (Reuters)
• Healthcare and drugmaker groups seek to revive challenge to US drug-pricing law (Reuters)
• UnitedHealth says hackers potentially stole a third of Americans' data (Reuters)
• Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1 (Reuters)

• UK’s MHRA To Use AI In Regulatory Review Process & RWD Analysis (Pink Sheet)
• Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives (Pink Sheet)
• Industry Calls For Caution Over EMA Supply Chain Recommendations (Pink Sheet)
• Industry Slates Decision To Exempt Parallel Importers From New Danish Stockpile Rules (Pink Sheet)
• Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain (Pink Sheet)
• Avid Bio fielding client inquiries due to China bill; Oxford Bio wants to double its revenues (Endpoints)

• Novartis’ $3 billion MorphoSys boondoggle (STAT)
• Novartis extends radiopharma plans with $1 billion acquisition (STAT)
• Regeneron's blockbuster eye drug posts weaker sales due to inventory impact (Reuters)
• Novo’s GLP-1 sales boost profits, yet full potential still curbed by supply squeeze (Endpoints)
• BridgeBio spins out oncology company as it focuses on heart drug (STAT)
• Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chief (STAT)
• Moderna expects CDC to view its RSV vaccine as equal to rival shots (Reuters)
• Transcarent, Glen Tullman’s health tech unicorn, raises $126 million (STAT)
• Exclusive: Spark co-founder launches new CNS gene therapy biotech with $54M (Endpoints)
• Context Therapeutics' $100M placement; Blueprint raises guidance for rare disease drug (Endpoints)
• As it cuts costs and pipeline, Bristol Myers hands back a cancer drug to Schrödinger (Endpoints)
• Biotech vets raise $67M to develop targeted activators for cancer (Endpoints)
• A once-public psychedelic biotech reemerges with $103M from MPM and Novo Holdings (Endpoints)
• Epigenetic editing startup Chroma lays off staff, focusing on reaching the clinic (Endpoints)

• Cardinal receives FDA warning letter over unapproved syringes (MedTech Dive)
• Medline to buy Ecolab’s surgical products for nearly $1B (MedTech Dive)
• Senseonics gets FDA clearance to pair CGM implant with insulin pumps (MedTech Dive)
• Labcorp gains FDA approval for companion diagnostic to Pfizer gene therapy (MedTech Dive)

• The U.S. needs a reliable supply of baby formula. A new bill in Congress can help (STAT)
• Brain biopsies on ‘vulnerable’ patients at Mount Sinai set off alarm bells at FDA, documents show (STAT)
• Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court (Reuters)
• Sarah Wicks Returns to HPM to Elevate Drug Development and Regulatory Practice (FDA Law Blog)